Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

Launched by ZHEJIANG UNIVERSITY · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called CNCT19 CAR-T cell therapy for patients with advanced hepatocellular carcinoma, which is a type of liver cancer. The main goal of the study is to see how safe and effective this therapy is for people whose cancer has progressed after previous treatments and who cannot undergo surgery or other local treatments. It is important to note that this trial is not yet open for participants.

To be eligible for this study, participants must be between 18 and 80 years old and have a confirmed diagnosis of hepatocellular carcinoma that is classified as stage II or III. They should have measurable tumors and must have already tried at least two previous treatments without success. Participants will need to be in reasonably good health to join, meaning they should have a stable condition and be expected to live for at least 12 more weeks. Throughout the trial, participants will receive the new therapy and be monitored closely for how they respond and any side effects they may experience. If you or a loved one are interested in this treatment, it's a good idea to discuss it with your healthcare provider to see if it may be a suitable option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 80 years, male or female;
• • Subjects voluntarily participated in the research and signed the Informed Consent Form (ICF) by themselves or their guardians;
• • Pathologically diagnosed with hepatocellular carcinoma, patients with China liver Cancer Staging (CNLC) stageII-III.;
• • HCC patients who are not suitable for surgical resection or local treatment (including ablation therapy, interventional therapy, and radiation therapy), or who experience recurrence or progression after surgery and/or local treatment, and who have previously received at least second-line systematic standardized treatment and have progressed or are intolerant to it;
• • According to RECIST 1.1 standard, there should be at least one measurable tumor lesion;
• • Tumor samples that meet the requirements (paraffin blocks or unstained sections with a quantity that meets the testing requirements specified in this study) within 2 years, and have CD19/CD68 double positive cells detected by immunohistochemistry or immunofluorescence;
• • Child-Pugh ≤ 7 and no history of hepatic encephalopathy;
• • ECOG 0-1;
• • Expected survival period ≥ 12 weeks;
• • The toxicity caused by previous treatment has stabilized or recovered to ≤ level 1 (except for cases judged by the researcher to be clinically insignificant)
• Exclusion Criteria:
• • Active brain metastasis;
• • Patients who have received or are waiting for organ transplantation;
• • Active autoimmune diseases that require systemic immunosuppressive therapy within the past 2 years, such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, etc;
• • Researchers evaluated that the proportion of intrahepatic tumors is greater than 50% of the entire liver; Or there may be tumor thrombus formation in the main portal vein, or tumor thrombus invasion into the mesenteric vein/inferior vena cava;
• • Use any of the following drugs or treatment methods within the specified time before cell collection: a Received local treatments such as surgical intervention, radiation therapy, ablation, etc. for the studied disease within 4 weeks prior to cell collection; b. Patients who have undergone major surgical procedures or significant trauma within 4 weeks prior to cell collection, or who are expected to undergo major surgery during the study period; c. Received immunotherapy such as anti-PD-1 and PD-L1 within one week prior to cell collection; d. Received chemotherapy drugs or targeted therapy such as sorafenib, regorafenib, lenvatinib within 2 weeks prior to cell collection; e. Used therapeutic doses of corticosteroids within 3 days prior to cell collection, but allowed to use topical and inhaled corticosteroids;
• • Within the past 5 years or simultaneously with other incurable malignant tumors, except for cervical cancer in situ, basal cell carcinoma of the skin, and ductal carcinoma in situ of the breast;
• • Individuals who have received other cell therapies or gene modified cell therapies in the past;
• • Central nervous system diseases that have clinical significance in the past or screening, such as epilepsy, epileptic seizures, cerebrovascular disease (ischemia/hemorrhage/cerebral infarction), cerebral edema, reversible posterior white matter encephalopathy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychiatric disorders;
• • There are chronic obstructive pulmonary disease, interstitial lung disease, and clinically significant abnormalities in lung function tests;
• • After evaluation by the researchers, it was found that the subject had a large amount of uncontrollable serous fluid accumulation (such as pleural effusion, abdominal effusion, pericardial effusion).